TriLink BioTechnologies® Solidifies IP Position with Awarded Patents for CleanCap® Capping Technology in China and Canada
TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), secures global patents for its CleanCap® Capping Technology, enhancing the production of synthetic mRNA for innovative medicines. The patents from China and Canada strengthen TriLink's intellectual property protection, complementing existing patents in major markets. CleanCap® technology has been pivotal in developing COVID-19 vaccines and promises faster drug commercialization.
The grant of patents for TriLink BioTechnologies' CleanCap® technology in China and Canada represents a strategic bolstering of the company's intellectual property portfolio on a global scale. This is particularly significant given the current landscape where synthetic mRNA technologies have gained prominence due to their role in COVID-19 vaccine development and potential in other therapeutic areas. The protection of CleanCap® technology in these key markets not only solidifies TriLink's competitive position but also has implications for the broader biotech sector, where patent landscapes can influence research directions, partnerships and market entry strategies.
The patented technology offers a more efficient approach to mRNA capping, which is a critical step in ensuring the stability and translational efficiency of mRNA therapeutics. By improving upon traditional capping methods, CleanCap® could facilitate faster and more cost-effective production of mRNA drugs, which may translate to increased access and reduced treatment costs for patients. However, it will be important to monitor how the enforcement of these patents impacts the industry, considering the balance between intellectual property rights and the need for collaborative efforts in public health emergencies.
From a financial perspective, the patented CleanCap® technology could be a key driver of revenue growth for Maravai LifeSciences, TriLink's parent company. The patents may enable TriLink to secure exclusive supply agreements with pharmaceutical companies developing mRNA-based therapeutics and vaccines. These agreements could provide a steady income stream through royalties or direct sales, enhancing Maravai's financial stability and attractiveness to investors.
Moreover, the announced reduction in manufacturing costs and improvements in mRNA yield and protein expression associated with CleanCap® M6 could lead to margin expansion for TriLink and, by extension, Maravai. It's worth noting that such cost efficiencies are critical in the highly competitive pharmaceutical manufacturing industry. Investors should consider the potential for Maravai's stock performance to reflect the operational efficiencies and market exclusivity afforded by these patents, particularly as the demand for mRNA technologies continues to grow.
The global expansion of TriLink's patent portfolio for CleanCap® technology is likely to have a significant impact on the market for mRNA therapeutics and vaccines. By securing patents in major markets, TriLink is well-positioned to capitalize on the burgeoning demand for mRNA technology, which has been spotlighted by the rapid development of COVID-19 vaccines. The company's ability to offer a patented technology that promises to reduce manufacturing times and costs while improving yields positions it as a potential leader in the supply chain for mRNA-based treatments.
However, competitors in the space will likely intensify their research and development efforts to innovate alternative capping technologies or workarounds to avoid patent infringement. It is crucial to monitor how these dynamics play out, as they could influence market share distribution and strategic alliances within the biotech industry. Additionally, the positive reception of CleanCap® M6 in the form of industry innovation recognitions suggests that the market perceives the technology favorably, which may boost TriLink's reputation and negotiating power in future deals.
02/21/2024 - 08:00 AM
TriLink’s CleanCap® Capping Technology is Patented Globally & TriLink is the Sole Authorized Manufacturer of CleanCap® Capping Analogs
SAN DIEGO --(BUSINESS WIRE)--
TriLink BioTechnologies (TriLink® ), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has been granted patents by the China National Intellectual Property Administration (CNIPA) and the Canadian Intellectual Property Office (CIPO). Patent numbers ZL 2023 1 0734863.0 and CA 2999274 are related to TriLink’s CleanCap® technology for the co-transcriptional capping of mRNAs – a critical component of the production of synthetic mRNA as drug developers and researchers strive to maximize the impact of mRNA-based therapeutics and vaccines.
These new issuances in China and Canada re-enforce the global strength and protection of TriLink’s intellectual property, adding new jurisdictions to the list of other major world markets in which CleanCap® technology is already patented , including the United States , European Union, Australia , Japan , Korea , and Hong Kong .
“mRNA technology continues to prove its value as a breakthrough modality for innovative medicines,” explained Drew Burch, President of Nucleic Acid Production at TriLink. “Obtaining patents in these key markets demonstrates the value of the CleanCap® technology and its use in mRNA in drugs for clinical studies and commercialization worldwide – the promise and pace of this industry is unmatched.”
The technology encompassed by the patents facilitates the production of mRNAs containing the major natural cap structures found in humans, a significant improvement over legacy capping methods such as enzymatic and ARCA. CleanCap® technology has been used in commercially approved COVID-19 mRNA and saRNA vaccines.
“TriLink’s CleanCap technology is helping to bring life-saving therapeutics and vaccines to market faster,” added Kurt Oreshack, Executive Vice President & General Counsel, Maravai LifeSciences. “These additional jurisdictions fortify the validity and strength of our global intellectual property.”
Last May, TriLink launched its most robust analog to date: CleanCap® M6 . The technology’s single-pot reaction capabilities are expected to shrink manufacturing times, reduce manufacturing costs by 20-40% *, increase protein expression by >30% , and increase mRNA yields with a purity profile of >95% . Its impressive performance and positive impact on the industry have earned CleanCap® M6 analog two industry innovation recognitions with Pharma Manufacturing The Medicine Maker .
To learn more about TriLink’s products and services, visit trilinkbiotech.com
*Data and customer insights garnered from a market assessment conducted by a third-party consulting firm on behalf of TriLink BioTechnologies in November 2022.
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.
For more information, visit trilinkbiotech.com
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit www.maravai.com .
Forward-looking statements
This press release contains, and Maravai’s officers and representatives may from time-to-time make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements regarding expected benefits associated with using CleanCap® technology, the expected impact of mRNA vaccines and therapeutics; Maravai’s future business capabilities; growth opportunities, including inorganic growth; and future innovations, constitute forward-looking statements and are identified by words like “promise,” “believe,” “expect,” “see,” “project,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240221073127/en/
Investor Contact: Deb Hart
ir@maravai.com
Media Contact: Liz Robinson of CG Life
lrobinson@cglife.com
Source: TriLink BioTechnologies
What is the ticker symbol for Maravai LifeSciences?
The ticker symbol for Maravai LifeSciences is MRVI.
What technology did TriLink BioTechnologies secure patents for?
TriLink BioTechnologies secured patents for its CleanCap® technology for the co-transcriptional capping of mRNAs.
In which countries were the patents granted to TriLink BioTechnologies?
The patents were granted by the China National Intellectual Property Administration (CNIPA) and the Canadian Intellectual Property Office (CIPO).
What are the benefits of CleanCap® technology in mRNA production?
CleanCap® technology facilitates the production of mRNAs with major natural cap structures, improving protein expression, reducing manufacturing costs, and increasing mRNA yields.
What industry recognitions has CleanCap® M6 analog received?
CleanCap® M6 analog has received two industry innovation recognitions with Pharma Manufacturing and The Medicine Maker.
